Roche Again Found Guilty of Most Serious Marketing Breach, This Time for Omitting Safety Information

The case centers on a webpage for Roche’s Rozlytrek, a drug used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. After viewing Roche’s U.K. resources website, an anonymous person complained to the Prescription Medicines Code of Practice Authority (PMCPA) that the content was misleading and not fair or balanced because it omitted critical information.